|Manufacturer:||Bayer Pharmaceuticals Corporation|
|Other Info:||Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516Made in Germany 08753825, R.3 11/04 Bay g 5421PRECOSE®/5202/0/8/USA-13 12573©2004 Bayer Pharmaceuticals Corporation Printed in U.S.A.|
PRECOSE®, as monotherapy, is indicated as an adjunct to diet to lower blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be managed on diet alone.
PRECOSE® may also be used in combination with a sulfonylurea when diet plus either PRECOSE® or a sulfonylurea do not result in adequate glycemic control.
Also, PRECOSE® may be used in combination with insulin or metformin.
The effect of PRECOSE® to enhance glycemic control is additive to that of sulfonylureas, insulin, or metformin when used in combination, presumably because its mechanism of action is different.In initiating treatment for type 2 diabetes mellitus, diet should be emphasized as the primary form of treatment.
Caloric restriction and weight loss are essential in the obese diabetic patient.
Proper dietary management alone may be effective in controlling blood glucose and symptoms of hyperglycemia.
The importance of regular physical activity when appropriate should also be stressed.
If this treatment program fails to result in adequate glycemic control, the use of PRECOSE® should be considered.The use of PRECOSE® must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.
PRECOSE® is contraindicated in patients with known hypersensitivity to the drug and in patients with diabetic ketoacidosis or cirrhosis.
PRECOSE® is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction.In addition, PRECOSE® is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.